These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. Zhou Z, Liu H, Yang Y, Zhou J, Zhao L, Chen H, Fei Y, Zhang W, Li M, Zhao Y, Zeng X, Zhang F, Yang H, Zhang X. Cancer Commun (Lond); 2022 May; 42(5):435-446. PubMed ID: 35357093 [Abstract] [Full Text] [Related]
3. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. Arthritis Rheum; 2011 Oct; 63(10):3032-7. PubMed ID: 21953088 [Abstract] [Full Text] [Related]
4. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Sultan SM, Ioannou Y, Isenberg DA. Rheumatology (Oxford); 2000 Oct; 39(10):1147-52. PubMed ID: 11035137 [Abstract] [Full Text] [Related]
6. Systemic lupus erythematosus and the risk of malignancy. Cibere J, Sibley J, Haga M. Lupus; 2001 Oct; 10(6):394-400. PubMed ID: 11434573 [Abstract] [Full Text] [Related]
7. Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: A Danish nationwide cohort study. Westermann R, Zobbe K, Cordtz R, Haugaard JH, Dreyer L. Lupus; 2021 Apr; 30(5):752-761. PubMed ID: 33497306 [Abstract] [Full Text] [Related]
8. Malignancy in Pediatric-onset Systemic Lupus Erythematosus. Bernatsky S, Clarke AE, Zahedi Niaki O, Labrecque J, Schanberg LE, Silverman ED, Hayward K, Imundo L, Brunner HI, Haines KA, Cron RQ, Oen K, Wagner-Weiner L, Rosenberg AM, O'Neil KM, Duffy CM, von Scheven E, Joseph L, Lee JL, Ramsey-Goldman R. J Rheumatol; 2017 Oct; 44(10):1484-1486. PubMed ID: 28765255 [Abstract] [Full Text] [Related]
9. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin's lymphoma: a nationwide population-based study. Wang LH, Wang WM, Lin SH, Shieh CC. Rheumatology (Oxford); 2019 Jul 01; 58(7):1245-1249. PubMed ID: 30726952 [Abstract] [Full Text] [Related]
10. Risk of malignancy in women with systemic lupus erythematosus. Sweeney DM, Manzi S, Janosky J, Selvaggi KJ, Ferri W, Medsger TA, Ramsey-Goldman R. J Rheumatol; 1995 Aug 01; 22(8):1478-82. PubMed ID: 7473469 [Abstract] [Full Text] [Related]
11. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Arthritis Rheum; 1997 Apr 01; 40(4):761-8. PubMed ID: 9125261 [Abstract] [Full Text] [Related]
14. Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up. Tallbacka KR, Pettersson T, Pukkala E. Scand J Rheumatol; 2018 Nov 01; 47(6):461-464. PubMed ID: 29318934 [Abstract] [Full Text] [Related]
15. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Ragnarsson O, Gröndal G, Steinsson K. Lupus; 2003 Nov 01; 12(9):687-91. PubMed ID: 14514131 [Abstract] [Full Text] [Related]
16. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, Tamaki Y, Matsumoto M, Hirabayashi K, Igarishi S, Masawa N, Nakamura S. Int J Surg Pathol; 2006 Jan 01; 14(1):43-8. PubMed ID: 16501834 [Abstract] [Full Text] [Related]
17. The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population. Ramirez M, Quintana G, Diaz-Gallo LM, Caminos J, Garces M, Cepeda L, Rondon F, Restrepo JF, Egea E, Garavito G, Robledo G, Martin J, Iglesias-Gamarra A. Clin Exp Rheumatol; 2012 Jan 01; 30(4):520-4. PubMed ID: 22704547 [Abstract] [Full Text] [Related]
18. Cancer risk in systemic lupus: an updated international multi-centre cohort study. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senécal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE. J Autoimmun; 2013 May 01; 42():130-5. PubMed ID: 23410586 [Abstract] [Full Text] [Related]
19. Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. Martinez SC, Mohamed M, Potts J, Abhishek A, Roddy E, Savage M, Bharadwaj A, Kwok CS, Bagur R, Mamas MA. Rheumatology (Oxford); 2020 Sep 01; 59(9):2512-2522. PubMed ID: 31990337 [Abstract] [Full Text] [Related]
20. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Parikh-Patel A, White RH, Allen M, Cress R. Cancer Causes Control; 2008 Oct 01; 19(8):887-94. PubMed ID: 18386139 [Abstract] [Full Text] [Related] Page: [Next] [New Search]